Gilead gets its go-ahead for blockbuster hopeful Vosevi, but will 12-week dosing give it trouble?
admin 19th July 2017 Uncategorised 0Gilead is out with a brand-new second-line hepatitis C treatment—but the length of its dosing schedule could set the company back down the line, one analyst predicts. Tuesday, U.S. regulators green-lighted Vosevi, a three-drug cocktail combining sofosbuvir and velpatasvir—already marketed together as pan-genotype med Epclusa—with new compound voxilaprevir.
More: Gilead gets its go-ahead for blockbuster hopeful Vosevi, but will 12-week dosing give it trouble?
Source: fierce